A summary of the Iodine Supplementation Study Protocol (I2S2)

a UK multicentre randomised controlled trial in preterm infants

Morgan Kayleigh, I2S2 team

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 µg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.
    Original languageEnglish
    Pages (from-to)282-289
    Number of pages8
    JournalNeonatology
    Volume105
    Issue number4
    DOIs
    Publication statusPublished - Jun 2014

    Fingerprint

    Premature Infants
    Iodine
    Randomized Controlled Trials
    Thyroxine
    Parenteral Nutrition
    Brain

    Cite this

    @article{24c69d43549f4c7c9654ef1e86b98058,
    title = "A summary of the Iodine Supplementation Study Protocol (I2S2): a UK multicentre randomised controlled trial in preterm infants",
    abstract = "This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 µg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.",
    author = "Fiona Williams and Robert Hume and Simon Ogston and Peter Brocklehurst and Morgan Kayleigh and Edmund Juszczak and {I2S2 team}",
    year = "2014",
    month = "6",
    doi = "10.1159/000358247",
    language = "English",
    volume = "105",
    pages = "282--289",
    journal = "Neonatology",
    issn = "1661-7800",
    publisher = "Karger",
    number = "4",

    }

    A summary of the Iodine Supplementation Study Protocol (I2S2) : a UK multicentre randomised controlled trial in preterm infants. / Kayleigh, Morgan; I2S2 team.

    In: Neonatology, Vol. 105, No. 4, 06.2014, p. 282-289.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A summary of the Iodine Supplementation Study Protocol (I2S2)

    T2 - a UK multicentre randomised controlled trial in preterm infants

    AU - Williams, Fiona

    AU - Hume, Robert

    AU - Ogston, Simon

    AU - Brocklehurst, Peter

    AU - Kayleigh, Morgan

    AU - Juszczak, Edmund

    AU - I2S2 team

    PY - 2014/6

    Y1 - 2014/6

    N2 - This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 µg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.

    AB - This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 µg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.

    UR - http://www.scopus.com/inward/record.url?scp=84895607600&partnerID=8YFLogxK

    U2 - 10.1159/000358247

    DO - 10.1159/000358247

    M3 - Article

    VL - 105

    SP - 282

    EP - 289

    JO - Neonatology

    JF - Neonatology

    SN - 1661-7800

    IS - 4

    ER -